EP Patent

EP2522665A1 — Crystalline sodium salt of an HIV integrase inhibitor

Assigned to Sandoz AG · Expires 2012-11-14 · 14y expired

What this patent protects

The present invention refers to a crystalline sodium salt of a compound of formula I (INN: Raltegravir) or a hydrate/solvate thereof as well as a process for obtaining the same.

USPTO Abstract

The present invention refers to a crystalline sodium salt of a compound of formula I (INN: Raltegravir) or a hydrate/solvate thereof as well as a process for obtaining the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP2522665A1
Jurisdiction
EP
Classification
—
Expires
2012-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.